01/13/15
02/13/15 5:00 PM Local time of applicant
USA: Alabama; Alaska; Arizona; Arkansas; California; Colorado; Connecticut; Delaware; Florida; Georgia; Hawaii; Idaho; Illinois; Indiana; Iowa; Kansas; Kentucky; Louisiana; Maine; Maryland; Massachusetts; Michigan; Minnesota; Mississippi; Missouri; Montana; Nebraska; Nevada; New Hampshire; New Jersey; New Mexico; New York City; New York; North Carolina; North Dakota; Ohio; Oklahoma; Oregon; Pennsylvania; Rhode Island; South Carolina; South Dakota; Tennessee; Texas; Utah; Vermont; Virginia; Washington, DC; Washington; West Virginia; Wisconsin; Wyoming
Grants to USA government agencies, businesses, non-profits, universities, and others for clinical trials designed to reduce high blood pressure among at-risk populations. January 13, 2015 is the deadline for the optional letter of intent. Awardees will evaluate various evidence based methods of blood pressure control among disproportionately affected populations such as racial and ethnic minorities, individuals with low socioeconomic status, and rural communities.
For the purposes of this FOA, high risk populations are those with an elevated risk of fatal and non-fatal cardiovascular disease outcomes and for whom it has been challenging to achieve a high rate (>75%) of blood pressure control. Many high risk populations are served in health care facilities such as Federally Qualified Health Centers (FQHCs), and community clinics. Many of these populations include a significant proportion of patients insured through Medicaid.
Planning, implementation, recruitment, retention, and dissemination, and other aspects of the trials will involve patients and key stakeholders in meaningful ways to assure the trial success.
Research Strategy: The project's overall goals are to improve clinical practice and lead to improvement in blood pressure control and other related patient-centered outcomes in disparities populations. Trials must be based on comparative study designs and must not include cost-effectiveness analyses. The overall active intervention strategy should be based on a comprehensive model of the remedial causes of disparities in hypertension among these high risk populations and the health care system in which these trials will occur.
Projects must be for patient-centered, comparative effectiveness research that specifically targets disparities in hypertension management. To avoid duplication, encourage innovation, and enhance utility of future research findings, the proposed trials must be innovative and different from previous and ongoing research by the proposing research team and past trials by other investigators.
Number of Grants:
Estimated Size of Grant:
The anticipated start date for the project is September 2015. The UH2 phase will be one year in length and the UH3 phase may be up to 4 years.
eRA Commons Help Desk (Questions regarding eRA Commons registration, submitting and tracking an application, documenting system problems that threaten submission by the due date, post submission issues)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
Finding Help Online: http://grants.nih.gov/support/index.html
Email: commons@od.nih.gov
Grants.gov Customer Support (Questions regarding Grants.gov registration and submission, downloading forms and application packages)
Contact Center Telephone: 800-518-4726
Web ticketing system: https://grants-portal.psc.gov/ContactUs.aspx
Email: support@grants.gov
Grants Info (Questions regarding application instructions and process, finding NIH grant resources)
Telephone: 301-435-0714
Email: GrantsInfo@nih.gov
Scientific/Research Contact(s)
Lawrence J. Fine, MD DrPH
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0305
Email: finel@nhlbi.nih.gov
Salina Waddy, MD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9135
Email: waddysp@mail.nih.gov
Peer Review Contact(s):
Director, Office of Scientific Review
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0270
Email: chiefreviewbranch@nhlbi.nih.gov
Financial/Grants Management Contact(s):
Tawana McKeither
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0166
Email: mckeitherta@nhlbi.nih.gov
Tijuanna DeCoster, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9231
Email: decostert@ninds.nih.gov
The letter of intent should be sent to:
Director, Office of Scientific Review
National Heart, Lung, and Blood Institute
6701 Rockledge Drive, Room 7214
Bethesda, MD 20892-7924 (Express Mail Zip: 20817)
Telephone: 301-435-0270
Email: nhlbichiefreviewbranch@nhlbi.nih.gov
Before starting your grant application, please review the funding source's website listed below for updates / changes / addendums / conferences / LOIs.